While we found that most patients were unlikely to benefit from intensifications, for patients with both severe inpatient hyperglycemia and uncontrolled outpatient blood glucose levels who may benefit from intensifications, simpler guideline-based insulin regimens, starting with single dose long-acting agents, is likely to lessen hypoglycemia risks compared with more complex short-acting or multidrug insulin regimens.27 The gene discussed is INS; the disease is Hyperglycemia.